Finance

Lists
Why is COLL down 2,78%?
Dive Deeper
COLL:NASDAQ
Collegium Pharmaceutical Inc
25,21 US$
-2,78%
(-0,72) 1D
25,44 US$
+0,91% (+0,23)
After hours
Closed: 19 ნოე, 16:00:01 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for COLL...
Open
25,81 US$
High
25,84 US$
Low
24,96 US$
Mkt. cap
783,41 მლნ.
Avg. vol.
630,62 ათ.
Volume
0,00
P/E ratio
25,59
52-wk high
50,79 US$
52-wk low
21,43 US$
EPS
0,98 US$
Beta
0,75
Shares outstanding
31,08 მლნ.
No. of employees
423
Open
25,81 US$
High
25,84 US$
Low
24,96 US$
Mkt. cap
783,41 მლნ.
Avg. vol.
630,62 ათ.
Volume
0,00
P/E ratio
25,59
52-wk high
50,79 US$
52-wk low
21,43 US$
EPS
0,98 US$
Beta
0,75
Shares outstanding
31,08 მლნ.
No. of employees
423
News stories
From web sources and news partners
About Collegium Pharmaceutical Inc
CEO-
Employees423
Founded2002
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Analyst ratings
Based on 6 analysts giving stock ratings to COLL in the past 3 months
Strong buy
Buy
5
Hold
1
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for COLL in the last 3 months.
Highest
Current 25,21 US$
60,00 US$ (+138,00%)
Average
45,50 US$ (+80,48%)
Lowest
28,00 US$ (+11,07%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jenna Davidner
Barclays
Buy
Maintained
41,00 US$
+62,6%
11/13/2026
Alexander Xenakis
Truist Financial
Buy
Reiterated
49,00 US$
+94,4%
11/06/2026
David Amsellem
Piper Sandler
Hold
Reiterated
28,00 US$
+11,1%
11/06/2026
Brandon Folkes
H.C. Wainwright
Buy
Reiterated
60,00 US$
+138%
11/06/2026
Les Sulewski
Oppenheimer
Buy
Reiterated
50,00 US$
+98,3%
10/09/2026
Unknown Analyst
Oppenheimer
Buy
Initiated
50,00 US$
+98,3%
09/23/2026
Daniel Clark
Leerink Partners
Buy
Initiated
45,00 US$
+78,5%
09/09/2026
Srikripa Devarakonda
Truist Financial
Buy
Maintained
49,00 US$
+94,4%
09/09/2026
Serge Belanger
Needham
Buy
Maintained
46,00 US$
+82,5%
08/06/2026
Unknown Analyst
Jefferies
Buy
Maintained
51,00 US$
+102,3%
03/20/2026
Last report
5 ნოე. 2026
Fiscal period
Q3 2026
1,96 US$ / 1,86 US$
+5,56%beat
Revenue / Est. (USD)
216,34 მლნ. / 216,03 მლნ.
+0,14%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
დეკ. 2025
მარ. 2026
ივნ. 2026
სექ. 2026
Revenue
205,45 მლნ.
193,52 მლნ.
199,88 მლნ.
216,34 მლნ.
Cost of goods sold
21,60 მლნ.
20,80 მლნ.
21,22 მლნ.
25,85 მლნ.
Cost of revenue
21,60 მლნ.
20,80 მლნ.
21,22 მლნ.
25,85 მლნ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
66,67 მლნ.
86,35 მლნ.
104,41 მლნ.
81,84 მლნ.
Operating expense
122,14 მლნ.
141,82 მლნ.
167,36 მლნ.
137,18 მლნ.
Total operating expenses
143,74 მლნ.
162,62 მლნ.
188,58 მლნ.
163,03 მლნ.
Operating income
61,71 მლნ.
30,90 მლნ.
11,30 მლნ.
53,31 მლნ.
Other non operating income
-
-
-
-
EBT including unusual items
29,04 მლნ.
18,74 მლნ.
-13,53 მლნ.
7,91 მლნ.
EBT excluding unusual items
45,98 მლნ.
18,74 მლნ.
-5,93 მლნ.
32,49 მლნ.
Income tax expense
12,07 მლნ.
4,24 მლნ.
1,52 მლნ.
-13,85 მლნ.
Effective tax rate
41,58%
22,65%
-11,23%
-175,22%
Other operating expenses
-
-
-
-
Net income
16,96 მლნ.
14,50 მლნ.
-15,05 მლნ.
21,76 მლნ.
Net profit margin
8,26%
7,49%
-7,53%
10,06%
Earnings per share
2,04
1,76
1,92
1,96
Interest and investment income
3,56 მლნ.
3,71 მლნ.
2,29 მლნ.
1,13 მლნ.
Interest expense
-19,29 მლნ.
-15,86 მლნ.
-19,52 მლნ.
-21,94 მლნ.
Net interest expenses
-15,73 მლნ.
-12,16 მლნ.
-17,23 მლნ.
-20,82 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
118,11 მლნ.
86,83 მლნ.
76,06 მლნ.
109,14 მლნ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google აპები